R&D JP Morgan 2023 - Astrocyte Pharmaceuticals pharmaphorum spoke with Astrocyte's Kevin Sheth, William Korinek, and James D. Lechleiter
News Ultragenyx to slash costs after Angelman trial failure Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
